Corifollitropin alfa - Merck & Co

Drug Profile

Corifollitropin alfa - Merck & Co

Alternative Names: Elonva; Follitropin-stimulating hormone long-acting; FSH long-acting; FSH-CTP; Long-acting follicle-stimulating hormone; MK-8962; ORG-36286; SCH-900962

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Organon
  • Developer Merck & Co; Universitair Ziekenhuis Brussel
  • Class Follicle stimulating hormones; Infertility therapies; Pituitary gonadotropins
  • Mechanism of Action Ovarian follicle stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Female infertility
  • Phase III Hypogonadism; Polycystic ovary syndrome

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Feb 2017 Phase-III clinical trials in Hypogonadism (In adolescents) in Russia (SC) (NCT03019575)
  • 11 Jan 2017 Merck Sharp & Dohme plans a phase III trial for Hypogonadotropic hypogonadism (Combination therapy, In adolescents) in Russia (SC, Injection) (NCT03019575)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top